Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Dengue Vaccine in Healthy Children (CYD23)
NCT00842530Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2009
- Primary completion
- Sep 2013
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever (2 arms), sponsored by Sanofi. Primary endpoint: Number of Symptomatic Virologically-Confirmed Dengue (VCD) Cases. Started Feb 2009; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT00842530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00842530.